Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients With Severe Hemophilia A

NCT01736475 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT01736475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01736475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients With Severe Hemophilia A
Lead sponsor
Baxalta now part of Shire
Phase
Phase 2/3
Overall status
Completed
Start date
January 31, 2013
Completion date
July 17, 2014
Enrollment
159 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a